Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
DigiTx Partners is a venture capital firm founded in 2016 and headquartered in San Francisco, California. The firm was established as a joint venture between Astellas Pharma, a global pharmaceutical company, and MPM Capital, a life-sciences venture capital firm. DigiTx Partners focuses on investing in early-stage companies that are innovating within the digital health sector. The firm aims to address complex challenges and inefficiencies in healthcare through technology and data-driven solutions.
As of now, DigiTx Partners manages a fund size of $75 million and has invested in a total of 23 companies. The firm is dedicated to supporting startups that enhance patient outcomes and healthcare delivery. DigiTx Partners reserves over 50% of its capital for follow-on investments, ensuring that its portfolio companies have the necessary resources to scale effectively. The firm operates primarily in North America, specifically the United States, and has established a reputation for its commitment to transforming healthcare through innovative technologies.
DigiTx Partners invests in a diverse range of digital health solutions, targeting early-stage companies that are at the forefront of healthcare innovation. Their investment strategy encompasses several key areas, including personalized medicine, data analytics, digital therapeutics, non-invasive medical devices, and software solutions. The firm emphasizes the importance of leveraging technology to enhance patient care, reduce costs, and improve health outcomes for health plans, employers, and health systems.
The firm typically invests in pre-seed, seed, and seed-plus stages, with check sizes ranging from $2 million to $5 million. DigiTx Partners seeks to acquire ownership stakes of 15% to 20% in its portfolio companies. Their investment thesis is built on three pillars: personalized medicine, data analytics, and digital therapeutics, all aimed at transforming healthcare through technology and meaningful data. The firm actively looks for innovative approaches that can address healthcare inefficiencies and improve patient outcomes.
DigiTx Partners has built a diverse portfolio of 23 early-stage companies, focusing primarily on digital health innovations. Notable portfolio companies include:
Among these, Tissue Analytics has achieved a notable exit, having been acquired by Net Health.
David J. Kim, MD, MBA: Managing Director. David is a physician-turned-venture capitalist with a background in internal medicine. He previously served as the Director of Urgent Care and Assistant Chief of Internal Medicine at Kaiser South San Francisco. He was recruited by Astellas and MPM Capital to lead DigiTx Partners.
Miraj Sanghvi: Partner. Miraj brings extensive experience in venture capital and healthcare investments, focusing on early-stage digital health companies.
Anish Aitharaju: Principal. Anish specializes in evaluating investment opportunities in the digital health sector and has a strong background in technology and healthcare.
Isabelle Chae: Investor. Isabelle focuses on sourcing and evaluating new investment opportunities within the digital health space.
Chihiro Hosoya, MSC, MBA: Venture Partner. Chihiro has a background in healthcare consulting and venture capital, providing strategic insights to portfolio companies.
Dan Riskin: Venture Partner. Dan has extensive experience in healthcare investments and supports portfolio companies in scaling their operations.
John Halamka, MD, MS: Advisor. John is a recognized leader in healthcare technology and provides strategic guidance to DigiTx Partners.
L. Jasmine Kim: Strategic Advisor. Jasmine offers insights into market trends and investment strategies within the digital health sector.
To pitch DigiTx Partners, founders should visit their website at digitxpartners.com or email info@digitx.com. A compelling pitch deck should include an overview of the technology, market analysis, and team qualifications. The firm typically responds within a few weeks, and while warm introductions are preferred, they are not strictly necessary.
In early 2024, DigiTx Partners made significant investments in several early-stage companies, including:
Additionally, DigiTx Partners has been featured in Global Venturing for its successful $75 million fund raise in 2018.
What are DigiTx Partners' investment criteria?
DigiTx Partners focuses on early-stage investments in digital health companies, particularly those innovating in personalized medicine, data analytics, and digital therapeutics. They seek companies that address inefficiencies in healthcare and improve patient outcomes.
How can I pitch DigiTx Partners?
Founders can pitch DigiTx Partners through their website at digitxpartners.com or by emailing info@digitx.com. A well-prepared pitch deck should include details about the technology, market opportunity, and team.
What makes DigiTx Partners different from other VCs?
DigiTx Partners is uniquely focused on the digital health sector, leveraging its connections in the healthcare industry to provide strategic guidance and support to portfolio companies. They reserve a significant portion of their capital for follow-on investments, ensuring continued support for scaling companies.
What is the geographic focus of DigiTx Partners?
The firm primarily invests in North America, specifically within the United States, targeting early-stage digital health companies that can benefit from their expertise and resources.
What is the typical check size for investments?
DigiTx Partners typically invests between $2 million and $5 million in early-stage companies, aiming for ownership stakes of 15% to 20%.
What kind of post-investment involvement can founders expect?
DigiTx Partners provides strategic guidance, industry connections, and support for follow-on funding to its portfolio companies, helping them navigate challenges and scale effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.